{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:27:47Z","timestamp":1794929267014,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10072-023-06750-8","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:02:58Z","timestamp":1679385778000},"page":"2923-2931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of comorbid diseases on clinical outcomes in patients with myasthenia gravis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-7276","authenticated-orcid":false,"given":"Huseyin Nezih","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-0695","authenticated-orcid":false,"given":"Hatice","family":"Karasoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-6423","authenticated-orcid":false,"given":"Ayse Nur","family":"Yuceyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-9416","authenticated-orcid":false,"given":"Ozgul","family":"Ekmekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"6750_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"6750_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","volume":"17","author":"A Evoli","year":"2021","unstructured":"Evoli A, Spagni G, Monte G, Damato V (2021) Heterogeneity in myasthenia gravis: considerations for disease management. Expert Rev Clin Immunol 17:761\u2013771. https:\/\/doi.org\/10.1080\/1744666X.2021.1936500","journal-title":"Expert Rev Clin Immunol"},{"key":"6750_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"6750_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","volume":"120","author":"UK Misra","year":"2020","unstructured":"Misra UK, Kalita J, Singh VK, Kumar S (2020) A study of comorbidities in myasthenia gravis. Acta Neurol Belg 120:59\u201364. https:\/\/doi.org\/10.1007\/s13760-019-01102-w","journal-title":"Acta Neurol Belg"},{"key":"6750_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4172\/2155-9562.1000317","volume":"6","author":"BC Diaz","year":"2015","unstructured":"Diaz BC, Flores-Gavil\u00e1n P, Garc\u00eda-Ramos G, Lorenzana-Mendoza NA (2015) Myasthenia Gravis and Its Comorbidities. J Neurol Neurophysiol 6:5. https:\/\/doi.org\/10.4172\/2155-9562.1000317","journal-title":"J Neurol Neurophysiol"},{"key":"6750_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","volume":"48","author":"A Nacu","year":"2015","unstructured":"Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE (2015) Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 48:362\u2013368. https:\/\/doi.org\/10.3109\/08916934.2015.1030614","journal-title":"Autoimmunity"},{"key":"6750_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17\u201323. https:\/\/doi.org\/10.1111\/ene.12599","journal-title":"Eur J Neurol"},{"issue":"3","key":"6750_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ane.13549","volume":"145","author":"E Klimiec-Moskal","year":"2022","unstructured":"Klimiec-Moskal E, Quirke M, Leite MI (2022) Comorbidities in older patients with myasthenia gravis - Comparison between early- and late-onset disease. Acta Neurol Scand 145(3):371\u2013374. https:\/\/doi.org\/10.1111\/ane.13549","journal-title":"Acta Neurol Scand"},{"key":"6750_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al (2016) International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"6750_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"6750_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"AIII Jaretzki","year":"2000","unstructured":"Jaretzki AIII, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"6750_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ane.12233","volume":"198","author":"JB Andersen","year":"2014","unstructured":"Andersen JB, Heldal AT, Engeland A, Gilhus NE (2014) Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl 198:26\u201331. https:\/\/doi.org\/10.1111\/ane.12233","journal-title":"Acta Neurol Scand Suppl"},{"key":"6750_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol 11:212. https:\/\/doi.org\/10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"6750_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/ane.12374","volume":"132","author":"JH Yeh","year":"2015","unstructured":"Yeh JH, Chen HJ, Lin CC, Chen YK, Chiu HC, Kao CH (2015) Risk of diabetes mellitus among patients with myasthenia gravis. Acta Neurol Scand 132:132\u2013138. https:\/\/doi.org\/10.1111\/ane.12374","journal-title":"Acta Neurol Scand"},{"key":"6750_CR15","doi-asserted-by":"publisher","first-page":"Doc12","DOI":"10.3205\/000239","volume":"14","author":"SR Sudulagunta","year":"2016","unstructured":"Sudulagunta SR, Sepehrar M, Sodalagunta MB, Nataraju AS, Raja SKB, Sathyanarayana D et al (2016) Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab. Ger Med Sci 14:Doc12. https:\/\/doi.org\/10.3205\/000239","journal-title":"Ger Med Sci"},{"issue":"175628561774913","key":"6750_CR16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1177\/1756285617749134.eCollection","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11(1756285617749134):2018. https:\/\/doi.org\/10.1177\/1756285617749134.eCollection","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"6750_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: Association of British Neurologists\u2019 management guidelines. Pract Neurol 15(3):199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"key":"6750_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/00207454.2017.1398160","volume":"128","author":"W Quan","year":"2018","unstructured":"Quan W, Xia J, Tong Q, Lin J, Zheng X, Yang X et al (2018) Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patient - a case report. Int J Neurosci 128:570\u2013572. https:\/\/doi.org\/10.1080\/00207454.2017.1398160","journal-title":"Int J Neurosci"},{"key":"6750_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.seizure.2016.08.003","volume":"41","author":"Z Lin","year":"2016","unstructured":"Lin Z, Si Q, Xiaoyi Z (2016) Association between epilepsy and systemic autoimmune diseases: A meta-analysis. Seizure 41:160\u2013166. https:\/\/doi.org\/10.1016\/j.seizure.2016.08.003","journal-title":"Seizure"},{"key":"6750_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00415-009-5091-9","volume":"256","author":"A Citterio","year":"2009","unstructured":"Citterio A, Beghi E, Millul A, Evoli A, Mantegazza R, Antozzi C et al (2009) Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 256:1221\u20131227. https:\/\/doi.org\/10.1007\/s00415-009-5091-9","journal-title":"J Neurol"},{"key":"6750_CR21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54:1041\u20131049. https:\/\/doi.org\/10.1002\/mus.25205","journal-title":"Muscle Nerve"},{"key":"6750_CR22","doi-asserted-by":"publisher","first-page":"117549","DOI":"10.1016\/j.jns.2021.117549","volume":"427","author":"SM Laakso","year":"2021","unstructured":"Laakso SM, Myllynen C, Strbian D, Atula S (2021) Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy. J Neurol Sci 427:117549. https:\/\/doi.org\/10.1016\/j.jns.2021.117549","journal-title":"J Neurol Sci"},{"key":"6750_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548\u20131554. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a41211","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06750-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06750-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06750-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T08:16:02Z","timestamp":1689236162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06750-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6750"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06750-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors do not have any competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to Declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The local ethics committee of the Ege University Medical School approved the study. Informed consent was\u00a0obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Informed Consent"}}]}}